EBNA-2
Epstein-Barr virus nuclear antigen 2 (EBNA-2) is a viral protein expressed by the Epstein-Barr virus (EBV), a member of the Herpesviridae family. EBNA-2 is one of the six nuclear antigens expressed during the latent phase of EBV infection and plays a crucial role in the transformation of infected B cells.
Structure[edit | edit source]
EBNA-2 is a transcriptional activator that lacks intrinsic DNA-binding activity. Instead, it interacts with the cellular DNA-binding protein RBP-Jκ (Recombination signal Binding Protein for immunoglobulin kappa J region), a component of the Notch signaling pathway. This interaction allows EBNA-2 to regulate the expression of both viral and cellular genes.
Function[edit | edit source]
EBNA-2 is essential for the immortalization of B cells by EBV. It acts as a transcriptional activator, modulating the expression of several viral and host genes that are critical for cell proliferation and survival. EBNA-2 activates the transcription of the EBV latent membrane proteins (LMP1, LMP2A, and LMP2B), which are key players in the transformation process.
Role in B Cell Transformation[edit | edit source]
EBNA-2 is required for the establishment of latent infection in B cells. It drives the expression of genes that promote cell cycle progression and inhibit apoptosis, thereby contributing to the transformation and proliferation of infected B cells. This transformation is a hallmark of EBV-associated diseases, such as infectious mononucleosis and certain types of lymphoma.
Pathogenesis[edit | edit source]
EBNA-2 is implicated in the pathogenesis of several EBV-associated malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma. By altering the expression of cellular genes, EBNA-2 can disrupt normal cell signaling pathways, leading to uncontrolled cell growth and oncogenesis.
Research and Clinical Implications[edit | edit source]
Understanding the function of EBNA-2 is critical for developing therapeutic strategies against EBV-associated diseases. Targeting the interaction between EBNA-2 and RBP-Jκ, or the downstream signaling pathways activated by EBNA-2, represents a potential approach for the treatment of EBV-related cancers.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
